domain protein-1/hypoxia-inducible factor-2α (EPAS-1/ HIF-2α) is a catabolic transcription factor that regulates osteoarthritis (OA) cartilage destruction.

Objectives: In this study, we examined whether microRNA-365 (miR-365) affects interleukin (IL)-1β-induced expression of catabolic factors in chondrocytes via regulation of HIF-2α.

Methods: Total RNA was isolated from normal and OA cartilage tissues and human chondrocytes. miR-365 expression was quantified by TaqMan assay. The effects of miR-365 on HIF-2α and HIF-2α-modulated genes were assessed by quantitative real-time reverse polymerase chain reaction (qRT-PCR), Western blot analysis, and enzyme-linked immunosorbent assay (ELISA). Direct interaction of miR-365 with the 3' untranslated region (UTR) of HIF-2α mRNA was examined using a luciferase reporter assay. Nitrite concentration was measured in culture medium using a Griess assay.

Results: miR-365 levels were significantly decreased in human OA cartilage relative to normal cartilage. Overexpression of miR-365 significantly suppressed IL-1β-induced expression of HIF-2α in human articular chondrocytes. Pharmacological inhibition of various IL-1β-associated signaling pathways revealed mitogen-activated protein kinase and nuclear factor-κB as the primary pathways driving IL-1β-mediated decreases in miR-365 and subsequent increase in HIF-2α expression. Using a luciferase reporter assay encoding the 3'UTR of human HIF-2α mRNA, we showed that overexpression of miR-365 significantly suppressed IL-1β-induced up-regulation of HIF-2α. Furthermore, miR-365 overexpression significantly suppressed IL-1β-induced expression of catabolic factors, including cyclooxygenase-2, inducible nitric oxide synthase, and matrix metalloproteinase-1, -3 and -13, and nitric oxide (NO) production in chondrocytes.

Conclusions: MiR-365 regulates IL-1β-stimulated catabolic effects in human chondrocytes by modulating HIF-2α expression.

References:
[1] Yang et al. Hypoxia-inducible factor-2alpha is a catabolic regulator of osteoarthritic cartilage destruction, Nat. Med. 16 (2010) 687–693.
[2] Akhtar et al. Haqqi, MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes, Arthritis Rheum. 62 (2010) 1361–1371.
[3] Park et al. MicroRNA-558 regulates the expression of cyclooxygenase-2 and IL-1beta-induced catabolic effects in human articular chondrocytes, Osteoarthritis Cartilage 21 (2013) 981–989.

Disclosure of Interest: None declared

THU0051   **ASSOCIATION BETWEEN BIOACTIVE TNF AND EULAR RESPONSE TO TNF INHIBITORS IN RHEUMATOID ARTHRITIS**

J. Poudroux[1], H. Marotte[1], J.-E. Gottenberg[2], S. Paul[3]. [1]Rheumatology, CHU Saint Etienne, Saint Priest en Jarez; [2]Rheumatology, CHU Strasbourg, Strasbourg; [3]Immunology, CHU Saint Etienne, Saint Priest en Jarez, France

Background: ROC study provided data to manage rheumatoid arthritis (RA) treatment after a failure to a first TNF blocker (1). We previously reported that high circulating TNF bioactivity was associated with good clinical response (2).

Objectives: To explore ability of TNF bioactivity to predict response to second TNF blocker.

Methods: Here, we assessed TNF bioactivity in 130 RA patients from the group rotation to a second TNF blocker at the time of randomisation and after 6 months. Clinical and biological data were recorded at baseline and 6 month with Eular response assessed at 6 month.

TNF bioactivity was assessed with HEK-Dual TNF cells adapted from our previous work (2). Due to non-normalised distribution, non parametrical analysis were performed.

Results: Baseline circulating TNF bioactivity was similar according to Eular response. However, circulating TNF bioactivity at 6 month was associated

with clinical response with low TNF bioactivity in responders. A ROC analysis suggested a cut-off at 0.320 with a sensitivity at 92% and a specificity at 41%.

Conclusions: After a failure of a first TNF blocker, circulating TNF bioactivity is not able to predict response to a second TNF blocker despite a lower level in responders compared to non-responders.

References:
[1] Gottenberg J-E, Brocq O, Perdriger A, Lassoued S, Berthelot J-M, Wendling D, et al. Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. JAMA. 2016 Sep 20;316(11):1172–80.
[2] Marotte H, Maslinski W, Miossec P. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther. 2005;7(1):R149–155.

Disclosure of Interest: None declared

THU0052   **LEVELS OF INFLAMMATORY SEROLOGIC BIOMARKERS IN HLA-B27 AND HLA-B15 POSITIVE PATIENTS WITH SPONDYLOARTHRITIS**

J. Londono[1], A.M. Santos[2], J.C. Rueda[2], P. Peña[2], I. Briceño[3], E.-L. Saldarriaga[2], J.-I. Angarita[2], E. Calvo[4], M. Avila[2], N. Martinez-Rodriguez[5], H. Cubides[2], V. Parra[2], J.F. Medina[6]. [1]Reumatología, Universidad de la Sabana-Hospital Militar Central, Bogotá; [2]Reumatología; [3]Facultad de Medicina, Grupo Genética Humana, Universidad de la Sabana, Chia; [4]Departamento de Imágenes diagnósticas, Universidad Nacional, Bogotá, Colombia; [5]Departamento de Investigación de Salud Comunitaria, Hospital Infantil de México Federico Gomez, Ciudad de Mexico, Mexico; [6]Unidad de Entrenamiento Clínico, Facultad de Medicina, Universidad de Navarra, Pamplona, Spain

Background: A main challenge in spondyloarthritis (SpA) management was the availability of reliable biomarkers related with disease activity, or predicting joint damage and the response to treatment. Although erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are currently used as biomarkers for disease activity, they lack sensitivity, specificity and reproducibility. With the understanding of SpA pathogenesis, additional biomarkers like metalloproteinase 3 (MMP-3), interleukin (IL)-1a, IL-6, lipopolysaccharide-binding protein (LBP), tumour necrosis factor a (TNFa), macrophage colony stimulating factor (M-CSF), interferon gamma (INF-g), IL-17 and IL-23, had been proposed

Objectives: We aimed to evaluate the associations of MMP-3, IL-1a, IL-6, M-CSF, LPB, IL-17 and IL-23 levels in SpA patients positive for HLA-B27 or HLA-B15

Methods: 178 patients (100 men and 78 women) with SpA according to ASAS criteria were included in the study. HLA typing was performed by PCR using the Biorad® HLA-SSP ABDR plates. The levels of TNFa, IL-1a, IL-6, INF-g and IL-17 were measured by a cytometric bead-array (CBA Flex Set) using a FACS Canto II Flow CytometerÔ. Enzyme-linked immunosorbent assay (ELISA) was used to determine serum levels of IL-23, M-CSFand MMP-3. CRP and LBP levels were measured by chemiluminescence. Statistical analysis was made with SPSS v19. For comparison of quantitative variables with a normal distribution we used the Student's *t*-test. Categorical variables were presented in frequency charts and percentages, and the Chi-squared test and Fisher's exact test were used when necessary, for comparing groups. Two-tailed P-value <0.05 was considered statistically significant

Results: Of the 178 patients, 70 were positive for HLA-B27, 34 for HLA-B15 and 74 had other HLA-B. According to ASAS classification criteria, 152 patients had axial SpA (axSpA) manifestations, 161 had peripheral SpA (pSpA) manifestations, and 148 patients had mixed axial and peripheral manifestations. Figure 1 shows the mean levels of inflammatory serologic biomarkers in these subgroups of patients


Figure 1. A. Disease activity biomarkers (CRP: C-reactive protein; LBP: lipopolysaccharide-binding protein) in axial spondyloarthritis (axSpA) and peripheral spondyloarthritis (pSpA); B. Cytokines (INFγ: interferon gamma; IL: interleukin; M-CSF: macrophage colony stimulating factor; TNFα: tumour necrosis factor alpha) in axSpA and pSpA; C. Disease activity biomarkers (MMP-3: metalloproteinase 3; ESR: erythrocyte sedimentation rate) in HLA-B27 and HLA-B15 positive SpA patients; D. Cytokines in HLA-B27 and HLA-B15 positive SpA patients

Conclusions: High levels of IL-17 and IL-23 were associated with the presence of HLA-B27, which mainly correlates with an axial presentation of the disease as

compared to HLA-B15 patients. Accordingly, the genotype (presence of HLA-B27 or HLA-B15) and phenotype (axial or peripheral involvement) may help physicians when considering a targeted therapy of SpA patients with IL-17 inhibition in a context of personalized medicine

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.5628

THU0053 **SELECTIVE ACTIVATION OF AN AMPK-CREB-NRF2-DEPENDENT PATHWAY BY CELECOXIB INDUCES VASCULOPROTECTIVE GENES AND MITIGATES AGAINST CARDIOVASCULAR RISK**

F. Alrashed, D. Calay, C.C. Thornton, A. Bauer, A. Kiprianos, D.O. Haskard, A. Seneviratne, J.J. Boyle, J.C. Mason. *Rheumatology and Vascular Sciences, Imperial College London, London, United Kingdom*

Background: Although concern remains about the athero-thrombotic risk posed by COX-2-selective inhibitors (COXIBs), the recent PRECISION trial demonstrated non-inferiority of moderate dose celecoxib when compared to naproxen and ibuprofen with respect to cardiovascular safety, with fewer actual CV events recorded for celecoxib. Moreover, celecoxib proved significantly safer than either comparator in regard to gastrointestinal events[1]. Given the markedly different cardiovascular risk associated with celecoxib and rofecoxib, we investigated the hypothesis that, in addition to cyclo-oxygenase inhibition, celecoxib specifically activates COX-2-independent AMP kinase (AMPK) signalling to exert protective effects in the vascular endothelium.

Objectives: To investigate COX-2-independent vasculoprotective signalling pathways activated by celecoxib in human endothelium.

Methods: *In vitro* studies of celecoxib, rofecoxib, ibuprofen and naproxen were performed on human umbilical vein and human aortic endothelial cells (HUVEC and HAEC). Inhibition of signalling pathways was achieved using siRNA. The vascular effects of celecoxib *in vivo* were studied in C57Bl/6 mice fed celecoxib (1000 ppm) or control chow (48 hrs). Aortic tissue was snap-frozen and sections studied by immunofluorescence confocal microscopy.

Results: At therapeutically relevant concentrations celecoxib ($1-10\mu$ M) induced the vasculoprotective protein heme oxygenase-1 (HO-1) in HUVEC and HAEC (EC) (p<0.01). In contrast, rofecoxib and the commonly used non-selective NSAIDs ibuprofen and naproxen failed to induce HO-1. Celecoxib derivative 2,5-dimethyl-celecoxib (DMC), which lacks COX-2 inhibition, also upregulated HO-1, implicating a COX-2-independent mechanism. Immunoblotting demonstrated that celecoxib and DMC induce $AMPK\alpha^{(Thr172)}$ and $CREB-1^{(Ser133)}$ phosphorylation leading to Nrf2 nuclear translocation (p<0.05). These responses were not seen with ibuprofen or naproxen, while siRNA depletion of $AMPK\alpha$ abrogated celecoxib-mediated CREB and Nrf2 activation (p<0.05). Acting via the same pathway, celecoxib induced additional cytoprotective genes including H-ferritin. *In vivo*, celecoxib similarly increased HO-1 and H-ferritin in murine aortic endothelium when compared to control-fed mice (p<0.05). Functionally, celecoxib treatment inhibited TNF-α-induced NF-κB p65$^{(Ser536)}$ phosphorylation by increasing AMPK activity. This attenuated VCAM-1 upregulation via induction of HO-1, as revealed by HO-1 siRNA (p<0.05). Similarly, celecoxib prevented the IL-1-mediated increase of IL-6 mRNA (p<0.01). These responses were not seen with ibuprofen or naproxen.

Conclusions: Celecoxib induces anti-inflammatory, anti-oxidant proteins HO-1 and H-ferritin in human vascular endothelium via a novel AMPK-CREB-Nrf2-dependent pathway. This mechanism may contribute to the important and marked differences in cardiovascular risk between celecoxib and rofecoxib. Understanding mechanisms underlying NSAID heterogeneity may ultimately lead to the development of safer anti-inflammatory drugs.

References:

[1] Nissen SE et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016;375:2519–29.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.2841

THU0054 **UTILITY OF SEROLOGICAL PARAMETERS IN GIANT CELL ARTERITIS FOR PREDICTING DISEASE COMPLICATIONS**

K. Lakota[1,2], J. Feichtinger[3,4], B. Burja[1], T. Kuret[1], P. Žigon[1], Ž. Rotar[1], R. Ješe[1], S. Sodin-Šemrl[1,2], S. Čučnik[1,5], G. Thallinger[3,4], M. Tomšič[1,6], A. Hočevar[1]. *[1]Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana; [2]FAMNIT, University of Primorska, Koper, Slovenia; [3]Institute of Molecular Biotechnology, Graz, Austria, Graz University of Technology; [4]OMICS Center Graz, BioTechMed Graz, Graz, Austria; [5]Faculty of Pharmacy; [6]Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia*

Background: Giant Cell Arteritis (GCA) is a systemic vasculitis affecting primarily large and medium sized arteries. Immediate high dose steroid treatment may prevent urgent complications, such as vision loss and cerebrovascular insults[1–3]. However, there is a clear lack of data on predicting serological markers and their association to clinical complications.

Objectives: To investigate serological parameters that support clinicians in predicting complications in a large, clinically well-characterized set of untreated GCA patients at time of diagnosis.

Methods: The study included 98 GCA patients (67% female) with a median (IQR) age 74.1 (67.3–78.8) years and a median (IQR) symptom duration time of 30 (20–90) days). Healthy blood donors (HDs, n=52, 61.5% female, median (IQR) age of 41.95 (20.4–63.1) years) served as controls. GCA complications studied were visual disturbances (including permanent loss of vision), relapses, peripheral artery involvement and claudication. Levels of 27 serum analytes were measured using Luminex xMAP Technology. Interleukin-6 (IL-6) and serum amyloid A (SAA) levels were tested using ELISA and nephelometry, respectively.

Results: The highest, significantly elevated analytes in GCA vs. HDs were SAA (85-fold > HDs mean values), IL-23 (63-fold) and IL-6 (11-fold). IL-13, α-fetoprotein and MMP-2 were significantly decreased in GCA, while levels of IL-2, IL-17A and TNF-α were unchanged. PCA analysis revealed a signature analyte profile positioning towards the HD cluster. SAA, CRP, haptoglobin, ESR, thrombocyte # and matrix metalloproteinase-1 (MMP-1) all negatively associated with visual disturbances, confirming our previous data. Age showed significant association to permanent visual loss, with older patients being more affected[3]. SAA, CRP and ESR at presentation were found to be predictive of relapsing disease, while MMP-2 negatively associated with relapse. VCAM-1, α-fetoprotein, MARCO and IL-27 were all negatively associated with peripheral artery involvement. MMP-2 and MARCO showed positive association with claudication, while IL-18 was negatively associated.

Conclusions: In our large study of untreated GCA patients we highlight the importance of using serological acute phase parameters, MMPs and other analytes for predicting complications.

References:

[1] Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003, 349:160–169.

[2] Nesher G: The diagnosis and classification of giant cell arteritis. J Autoimmun 2014, 48–49:73–75.

[3] Hocevar A et al. Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis: A Prospective Longitudinal Study. Medicine (Baltimore) 2016, 95:e3210.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.3467

THU0055 **LOW MOLECULAR WEIGHT BAFF SIGNALING INHIBITORS AMELIORATE IL-6, IL-10 AND IGG PRODUCTION IN VITRO AND IN VIVO MODELS OF AUTOIMMUNE DISEASES**

K. Yoshimoto[1], K. Suzuki[1], K. Sugahara[2], T. Takeuchi[1]. *[1]Keio University School of Medicine, Tokyo; [2]Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan*

Background: In our previous study, we reported that soluble BAFF (sBAFF) robustly enhanced IL-6 production by peripheral monocytes of patients with primary Sjogren's syndrome (pSS) and that the expression level of a BAFF receptor (BR3) was significantly elevated in pSS monocytes. We also found that the proportion of BR3-positive monocytes to total monocytes was positively and significantly correlated with the serum IgG level of pSS patients. Investigation of the interaction of monocytes and B cells showed that IgG production by B cells was enhanced by sBAFF-stimulated monocytes. These data collectively suggest that the elevated expression of BR3 on monocytes is involved in IgG overproduction by B cells which is often observed in pSS, and that BAFF signaling via BR3 is a possible therapeutic target to treat pSS. A high throughput screening of a low molecular weight compound library successfully discovered two pyrrolopyrimidine derivatives, BIK12 and BIK13, which inhibit sBAFF binding to BR3. We found that these compounds inhibited not only IL-6 production by BAFF-stimulated monocytes, but also IgG production by B cells co-cultured with the monocytes.

Objectives: To elucidate the mechanism of inhibitory activities of these compounds on BAFF signaling pathways, we measured production of IL-10 as well as IL-6 by monocytes *in vitro*, both of which work for B cell activation. In addition, we analyzed *in vivo* effects of the compounds on production of autoantibody and cytokines in autoimmune disease model mice.

Methods: Peripheral monocytes and B cells were prepared from healthy individuals. The monocytes were stimulated with sBAFF and cultured *in vitro* with or without peripheral B cells in the presence of BIK-12 or BIK-13. The amounts of IL-6, IL-10 and IgG were measured by ELISA. BIK-13 was administered intraperitoneally to MRL/lpr mice, an animal model of autoimmune diseases, three times a week for 6 months. Serum levels of an anti-ds DNA antibody, IL-6 and IL-10 were measured by ELISA.

Results: sBAFF enhanced the production of not only IL-6, but also IL-10 by peripheral monocytes *in vitro*. As expected, BIK12 and BIK-13 significantly suppressed production of IL-6 and IL-10 by BAFF-stimulated monocytes *in vitro* in a dose dependent manner. Notably, IgG production by B cells co-cultured *in vitro* with sBAFF-stimulated monocytes was significantly suppressed by these compounds. The compounds did not exhibit toxicities to the cells in the dose range. These data suggest that BAFF signaling via BR3 lead to production of IL-6 and IL-10 in monocytes, and the cytokines in turn mediates the signal to B cells resulting in IgG overproduction. Interestingly, serum levels of an anti-dsDNA antibody, IL-6 and IL-10 in MRL/lpr mice received BIK13 simultaneously declined as compared to control mice. These data collectively suggest that the compound was also efficacious *in vivo*.

Conclusions: BIK-13, a pyrrolopyrimidine derivative, suppressed IgG production